- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01547117
Dietary Salt in Postural Tachycardia Syndrome
Study Overview
Status
Conditions
Detailed Description
Study Day 1
- Start 150 milliequivalents (mEq) Na+/day diet (POTS patients as inpatients; healthy control subjects with clinical research center (CRC)- provided outpatient diet)
- Start a 24h urine collection (for Na+, K+, Cr, fractionated catecholamines)
- Blood work
- Blood volume - carbon monoxide rebreathing
Study Day 2
- Complete 24h urine
- Start STUDY DIET (10 mEq Na+/day or 300 mEq Na+/day in a random order) after 3 meals of 150 mEq Na+/day are complete; water ad lib
Study Day 3 - 5
- Continue STUDY DIET; water ad lib
- On Day 5, a 24 hr holter combined ECG monitor will be placed on the subjects.
Study Day 6
- Continue STUDY DIET; water ad lib
- Remove 24h Holter combined ECG monitor and BP monitor from subject
- Start a 24h urine collection (for Na+, K+, Cr, fractionated catecholamines)
- Complete questionnaires
- Nothing by mouth (NPO) after midnight for study next day
Study Day 7 (BIG DAY)
- Awaken early (~6am) to void (still collecting 24h urine)
- Patient returns to bed, IV catheter inserted
- Posture Study (in morning; between 7-8am ideally)
- Blood pressure and heart rate will be measured while supine and then while standing for up to 30 minutes
- We will draw 3 tablespoons of blood in each body position to measure hormones that regulate blood pressure and blood volume
- Hormones to verify the subject's phase of menstrual cycle
- Serum/plasma aliquots for future analysis
- Subjects will rate symptoms during supine period and at end of stand using Vanderbilt Orthostatic Symptoms Score (VOSS)
- Total Blood Volume (DAXOR)- using injection of iodinated I-131 tagged human serum albumin nominally 25 micro-Ci of radiation blood samples drawn through IV catheter before injection and for ~30 minutes post-injection (total - 25 ml)
- This will be done after supine assessment, but before standing the subject up
- Autonomic Function Test with Cardiac Output and Brief Tilt
- The subject will be tilted up to 60-75 degrees head-up tilt for up to 10 minutes to measure the changes in heart rate and blood pressure and symptoms with upright challenge.
- Blood volume - carbon monoxide rebreathing
- Exercise Capacity Test (in the afternoon) Will estimate maximal oxygen consumption (VO2 max) This test will be conducted on a stationary bicycle. Effort will be gradually increase while expired air is measured during exhaustive physical work.
All procedures are repeated at least a month later with the 2nd level of dietary salt. (Randomized to high or low salt to the first phase, the second phase is the remaining level)
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Vanderbilt University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosed with postural tachycardia syndrome by the Vanderbilt Autonomic Dysfunction Center
- Increase in heart rate ≥30 beats/min with position change from supine to standing (10 minutes)
- Chronic symptoms consistent with POTS that are worse when upright and get better with recumbence
- Age between 18-50 years old
- Non-smokers
- Premenopausal patients with POTS and healthy volunteers
- Only female participants are eligible.
- Since 80-90% of POTS patients are female, and there can be differences in measures with the menstrual cycle, including a small number of males might introduce a significant amount of noise.
- Able and willing to provide informed consent
Exclusion Criteria:
- Smokers
- Overt cause for postural tachycardia, i.e., acute dehydration
- Significant cardiovascular, pulmonary, hepatic, or hematological disease by history or screening results
- Pregnant (positive pregnancy test) or breastfeeding
- Hypertension defined as supine resting BP>145/95 mmHg off medications or needing antihypertensive medication
- Other factors which in the investigator's opinion would prevent the participant from completing the protocol, including poor compliance during previous studies or an unpredictable schedule
- Unable to give informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: High Sodium Level
POTS and healthy controls will be randomly assigned the order of dietary sodium levels.
All procedures are performed at both levels.
The high sodium diet will provide 300 milliequivalents (mEq) sodium/day.
|
we will measure the amount of hemoglobin and myoglobin in the body by a procedure called CO rebreathing.
One teaspoon of blood is taken before and after a small amount of CO has been absorbed into the bloodstream.
Other Names:
Using injection of iodinated I-131 tagged human serum albumin nominally 25 microcuries of radiation, blood samples are drawn before and 30 minutes after injection.
Other Names:
subjects breath room air through a mouthpiece and exhale the air into a tube that connects to a machine (metabolic cart) that analyzes carbon dioxide and oxygen content, which allows the investigator to calculate the amount of oxygen they are using under resting and exercise conditions.
Other Names:
Blood pressure and heart rate will be measured while supine and then while standing for up to 30 minutes.
Blood will be drawn in each position to measure hormones that regulate blood pressure and blood volume.
Other Names:
|
Experimental: Low Sodium Dietary Level
POTS and healthy controls will be randomly assigned the order of dietary sodium levels.
All procedures are performed at both levels.
The low sodium diet will provide 10 mEq sodium/day.
|
we will measure the amount of hemoglobin and myoglobin in the body by a procedure called CO rebreathing.
One teaspoon of blood is taken before and after a small amount of CO has been absorbed into the bloodstream.
Other Names:
Using injection of iodinated I-131 tagged human serum albumin nominally 25 microcuries of radiation, blood samples are drawn before and 30 minutes after injection.
Other Names:
subjects breath room air through a mouthpiece and exhale the air into a tube that connects to a machine (metabolic cart) that analyzes carbon dioxide and oxygen content, which allows the investigator to calculate the amount of oxygen they are using under resting and exercise conditions.
Other Names:
Blood pressure and heart rate will be measured while supine and then while standing for up to 30 minutes.
Blood will be drawn in each position to measure hormones that regulate blood pressure and blood volume.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plasma Volume
Time Frame: after 7 days of each dietary sodium level
|
Plasma volume (PV) was determined by the indicator tracer-dilution technique, using the DAXOR Blood Volume Analyzer (BVA)-100 system (DAXOR Corporation), on Day 7 of the low sodium and high sodium dietary interventions.
Outcome data are the absolute values for PV on Day 7 for each diet.
|
after 7 days of each dietary sodium level
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Magnitude of Suppression of Plasma Renin Activity (From Low Sodium to High Sodium Diets)
Time Frame: Upright blood samples were collected after up to 30 minutes of standing on the 7th day of each dietary sodium intervention
|
Whether upright plasma renin activity was modified appropriately by changes in dietary sodium in POTS & healthy controls.
Outcome data are the absolute values for upright plasma renin activity on Day 7 of each diet.
|
Upright blood samples were collected after up to 30 minutes of standing on the 7th day of each dietary sodium intervention
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Magnitude of Suppression of Serum Aldosterone (From Low Sodium to High Sodium Diets)
Time Frame: Upright blood samples were collected after up to 30 minutes of standing on the 7th day of each dietary sodium intervention
|
Whether upright serum aldosterone was modified appropriately by changes in dietary sodium in POTS patients & healthy controls.
Outcome data are the absolute values for upright serum aldosterone on Day 7 of each diet.
|
Upright blood samples were collected after up to 30 minutes of standing on the 7th day of each dietary sodium intervention
|
Magnitude of Orthostatic Tachycardia
Time Frame: Supine and upright heart rates were measured on Day 7 of High Sodium and Low Sodium diet.
|
Whether the magnitude of the heart rate increase that occurs in patients with POTS when moving from a supine to an upright position is attenuated by a High Sodium diet relative to a Low Sodium diet. Heart rate was assessed after overnight rest and fasting after midnight, following at least 60 minutes of lying quietly. Heart rate was then measured at intervals after subjects had been standing for up to 30 minutes (as tolerated). Orthostatic tachycardia was calculated as the difference between standing and lying heart rates. Data are presented for 5 minutes standing (or maximal stand if <5 minutes) since several patients were unable to stand for 10 minutes. Data in POTS patients were compared to that of Healthy Controls. |
Supine and upright heart rates were measured on Day 7 of High Sodium and Low Sodium diet.
|
Upright Symptom Score
Time Frame: Upright symptoms were assessed on the 7th day of diet.
|
Whether upright symptoms were improved in patients with POTS on a High Sodium diet relative to a Low Sodium diet. Patients were asked to report their standing symptom burden at the end of the Stand portion of the posture study, using the Vanderbilt Orthostatic Symptoms Scale (VOSS). They rated the severity of nine symptoms (palpitations, lightheadedness, mental confusion, blurred vision, shortness of breath, tremulousness, chest discomfort, headache, and nausea) on a scale from a minimum of 0 (reflecting an absence of symptoms) to a maximum of 10. The sum of the scores for the 9 symptoms was used to measure orthostatic symptom burden. Higher scores represent worse symptoms. |
Upright symptoms were assessed on the 7th day of diet.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Alfredo J Gamboa, MD, Vanderbilt University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Heart Diseases
- Cardiovascular Diseases
- Nervous System Diseases
- Disease
- Arrhythmias, Cardiac
- Cardiac Conduction System Disease
- Autonomic Nervous System Diseases
- Primary Dysautonomias
- Orthostatic Intolerance
- Syndrome
- Tachycardia
- Postural Orthostatic Tachycardia Syndrome
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites
- Gasotransmitters
- Carbon Monoxide
Other Study ID Numbers
- 111261
- R01HL102387 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Postural Orthostatic Tachycardia Syndrome
-
argenxIqvia Pty LtdRecruitingPost-COVID Postural Orthostatic Tachycardia Syndrome Postural Orthostatic Tachycardia SyndromeUnited States
-
Mayo ClinicNot yet recruitingPostural Tachycardia Syndrome | Postural Orthostatic Tachycardia Syndrome | Autonomic Dysfunction | POTS - Postural Orthostatic Tachycardia SyndromeUnited States
-
Jami WarrenRecruitingPOTS - Postural Orthostatic Tachycardia SyndromeUnited States
-
Vanderbilt University Medical CenterNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...CompletedPostural Tachycardia Syndrome (POTS)United States
-
Vanderbilt University Medical CenterNational Heart, Lung, and Blood Institute (NHLBI)RecruitingPostural Tachycardia Syndrome (POTS)United States
-
Lund UniversityRegion SkaneRecruitingPOTS - Postural Orthostatic Tachycardia SyndromeSweden
-
Vanderbilt University Medical CenterCompletedPostural Orthostatic Tachycardia Syndrome (POTS)United States
-
New York Medical CollegeNational Institutes of Health (NIH)CompletedOrthostatic Intolerance | Postural Orthostatic Tachycardia Syndrome (POTS) | POTSUnited States
-
University of CalgaryDysautonomia InternationalRecruiting
-
University of CalgaryCompleted
Clinical Trials on Blood Volume
-
Mayo ClinicCompletedCongestive Heart FailureUnited States
-
Mayo ClinicCompletedHeart FailureUnited States
-
Virginia Commonwealth UniversityDaxor CorporationWithdrawn
-
Mayo ClinicSphingotec GmbHCompletedHeart Failure | Decompensated Heart Failure | Systolic Heart Failure | Volume OverloadUnited States
-
Hadassah Medical OrganizationCompleted
-
NYU Langone HealthDaxor CorporationTerminatedHeart FailureUnited States
-
Centre hospitalier de l'Université de Montréal...The Kidney Foundation of CanadaRecruitingAcute Kidney Injury | Fluid Overload | Chronic Kidney Failure | Intradialytic Hypotension | Chronic Kidney Disease Stage 5 on DialysisCanada
-
University of FloridaNational Aeronautics and Space Administration (NASA)CompletedMicrogravity Exposed Endothelial CellsUnited States
-
University of FloridaFlorida Space InstituteCompletedCardiovascular DiseasesUnited States
-
Central and North West London NHS Foundation TrustBritish HIV Association (BHIVA)Not yet recruitingHIV Infections | Hepatitis B